568 related articles for article (PubMed ID: 10713627)
1. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice.Société Française de Greffe de Moelle.
Lapierre V; Kuentz M; Tiberghien P
Bone Marrow Transplant; 2000 Mar; 25(5):507-12. PubMed ID: 10713627
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
Rowley SD; Liang PS; Ulz L
Bone Marrow Transplant; 2000 Oct; 26(7):749-57. PubMed ID: 11042656
[TBL] [Abstract][Full Text] [Related]
3. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation.
Snell M; Chau C; Hendrix D; Fox R; Downes KA; Creger R; Meyerson H; Telen MJ; Laughlin MJ; Lazarus HM; Yomtovian R
Bone Marrow Transplant; 2006 Jul; 38(2):135-40. PubMed ID: 16751785
[TBL] [Abstract][Full Text] [Related]
4. Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation.
Zupańska B; Zaucha JM; Michalewska B; Malinowska A; Brojer E; Hellmann A
Transfusion; 2005 Jan; 45(1):16-20. PubMed ID: 15647013
[TBL] [Abstract][Full Text] [Related]
5. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.
Canals C; Muñiz-Díaz E; Martínez C; Martino R; Moreno I; Ramos A; Arilla M; Boto N; Pastoret C; Remacha A; Sierra J; Madoz P
Transfusion; 2004 Nov; 44(11):1603-11. PubMed ID: 15504166
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
[TBL] [Abstract][Full Text] [Related]
8. Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation.
Franchini M; Gandini G; Aprili G
Bone Marrow Transplant; 2004 Jun; 33(12):1169-72. PubMed ID: 15094753
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning.
Worel N; Greinix HT; Supper V; Leitner G; Mitterbauer M; Rabitsch W; Fischer G; Rosenmayr A; Höcker P; Kalhs P
Transfusion; 2007 Aug; 47(8):1494-502. PubMed ID: 17655594
[TBL] [Abstract][Full Text] [Related]
10. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation.
Kim JG; Sohn SK; Kim DH; Baek JH; Lee KB; Min WS; Kim CC; Lee MH; Lee JJ; Chung IJ; Kim HJ; Lee JW
Bone Marrow Transplant; 2005 Mar; 35(5):489-95. PubMed ID: 15654350
[TBL] [Abstract][Full Text] [Related]
11. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation.
Yazer MH; Triulzi DJ
Curr Opin Hematol; 2007 Nov; 14(6):664-70. PubMed ID: 17898572
[TBL] [Abstract][Full Text] [Related]
12. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation.
Ozkurt ZN; Yegin ZA; Yenicesu I; Aki SZ; Yagci M; Sucak GT
Transplant Proc; 2009 Nov; 41(9):3851-8. PubMed ID: 19917400
[TBL] [Abstract][Full Text] [Related]
13. [Erythrocyte transfusion practices after allogeneic hematopoietic stem cell transplantation].
Lapierre V; Kuentz M; Tiberghien P
Transfus Clin Biol; 1999 Apr; 6(2):148-52. PubMed ID: 10339805
[TBL] [Abstract][Full Text] [Related]
14. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B.
Schetelig J; Breitschaft A; Kröger N; Zabelina T; Ebell W; Bornhäuser M; Haack A; Ehninger G; Salama A; Siegert W;
Transfusion; 2005 May; 45(5):779-87. PubMed ID: 15847669
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
17. Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism.
Mueller RJ; Stussi G; Odermatt B; Halter J; Schanz U; Seebach JD
Xenotransplantation; 2006 Mar; 13(2):126-32. PubMed ID: 16623806
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation.
Wirk B; Klumpp TR; Ulicny J; Herman JH; Gajewski JL; Martin ME; Emmons RV; Mangan KF
Transfusion; 2008 Jan; 48(1):163-8. PubMed ID: 17900280
[TBL] [Abstract][Full Text] [Related]
19. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.
Stussi G; Muntwyler J; Passweg JR; Seebach L; Schanz U; Gmür J; Gratwohl A; Seebach JD
Bone Marrow Transplant; 2002 Jul; 30(2):87-93. PubMed ID: 12132047
[TBL] [Abstract][Full Text] [Related]
20. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
